Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — 2020 Wells Fargo Virtual Healthcare Conference
28 slides from Sutro Biopharma's conference presentation, Sep 9, 2020
Slide 1: Company Overview 2020 Wells Fargo Virtual Healthcare Conference
Company Overview 2020 Wells Fargo Virtual Healthcare Conference NASDAQ: STRO Bill Newell, CEO Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: The Sutro Vision: Novel Platform Delivering on Promise to Change the Future of Oncology
The Sutro Vision Novel Platform Delivering on Promise to Change the Future of Oncology PLATFORM XpressCF® and XpressCF+™ Precision Protein Engineering Generates Superior Molecules Integrated Manufacturing Facility Is Strategic Asset Proven IND Engine 3 Potential Best-in-Class ADCs in Phase 1 2 more
Slide 4: Sutro's Approach: Delivering Potentially Best-in-Class ADCs and Cytokine Conjugates
Sutro’s Approach Delivering Potentially Best-in-Class ADCs and Cytokine Conjugates Widening the Therapeutic Index is Key to Achieving Optimized Performance Rapid iterative design Selection of specific sites for conjugation for optimal performance Homogenous end-products XpressCF® – Our Truly Empiric
Slide 5: Sutro Clinical Pipeline: Owned and Partnered Programs
Sutro Clinical Pipeline Owned and Partnered Programs Program Discovery Preclinical Phase 1/1b Phase 2/3 Milestone Commercial Rights Ovarian and Endometrial Cancer FolRα - Targeting ADC STRO-002 CD74 - Targeting ADC STRO-001 Multiple Oncology Programs including iADCs Cytokine Derivatives Commence Dos
Slide 6: Encouraging Progress Across Multiple Programs
Encouraging Progress Across Multiple Programs* *Based on data or events previously disclosed publicly **Based on 33 evaluable patients at ≥2.9 mg/kg STRO-002 (FolRα ADC) – OC all comers Dose escalation enrollment complete (39 patients enrolled, 34 ≥ 2.9 mg/kg & 38% remain on study) Promising Anti-Tu
Slide 7: Delivering On Our Collaborations
Delivering On Our Collaborations ~ $384 Million in Payments Received through June 30, 2020 from Collaborators Cytokine Derivatives 1st of 2 programs with lead optimization achieved in 18 months ~$101M total funding received Up to $1.6B potential future milestones for all programs Mid single digit to
Slide 8: FolRα-Targeting ADC STRO-002
FolRα – Targeting ADC Phase 1 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers STRO 002
Slide 9: STRO-002 Structure and Design
STRO-002 Structure and Design Optimized molecule provides potential for best-in-class STRO 002 STRO-002 Structure of hemiasterlin linker-warhead following conjugation STRO-002 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids STRO-002 has a drug-antibo
Slide 10: Heavily Pretreated Ovarian Cancer Patients: Demographics/Dose Levels
Heavily Pretreated Ovarian Cancer Patients: Demographics/Dose Levels Data as of August 31, 2020 Characteristic Total N = 39 (%) Age, median (range), years 61 (48-79) Tumor type EOC 30 (77) Fallopian tube 7 (18) Primary peritoneal 2 (5) ECOG PS 0 23 (59) 1 16 (41) Median time from diagnosis (range) 3
Slide 11: STRO-002 is Generally Well Tolerated
STRO-002 is Generally Well Tolerated 87% of AEs were Grade 1–2 No need for prophylactic corticosteroid eyedrops Neutropenia readily reverses within 1 week, without the need for G-CSF Peripheral neuropathy/arthralgia can be managed with dose reduction/delay without evidence of compromised efficacy Sa
Slide 12: Robust Anti-Tumor Activity in Heavily Pre-Treated, Unselected Patients
Best % change in sum of target lesions from baseline Evaluable patients treated at ≥ 2.9 mg/kg, N=29 4 pts off study before post baseline scan 1 pt ongoing, not yet at first post baseline scan Data as of August 31, 2020 Robust Anti-Tumor Activity in Heavily Pre-Treated, Unselected Patients +30 +6 +1
Slide 13: Partial Response with 74% Tumor Reduction
Partial Response with 74% Tumor Reduction Patient Continues on Treatment Confirmed PR after 4 cycles Baseline 3/16/20 06/29/20 57-year-old woman with platinum resistant ovarian cancer progressing after 4 prior regimens received STRO-002 at 5.2 mg/kg and remains on study treatment
Slide 14: Long Duration on Study and Disease Control Observed
Long Duration on Study and Disease Control Observed in Unenriched, Heavily Pre-Treated Ovarian Cancer Patients Duration calculated as time from first dose to last dose given (on study) or date of PD (off study). Data as of Aug 31, 2020 STRO 002 0 5 10 15 20 25 30 35 40 45 50 55 60 2.9 mg/kg 2.9 mg/k
Slide 15: High Rates of CA-125 Responses are Associated with Anti-Tumor Activity
STRO 002 High Rates of CA-125 Responses are Associated with Anti-Tumor Activity *Gynecologic Cancer InterGroup (GCIG) criteria requires an elevated baseline CA-125 level of at least twice the upper limit of normal 10/25 (40%) have confirmed CA-125 reductions ≥ 50% that is maintained and confirmed 28
Slide 16: STRO-002 Clinical Data Readout
CA-125 Reduction in level of ≥50% 57% (12/21) 72% (18/25) STRO-002 Clinical Data Readout April 20th, 2020 Interim Analysis August 31st, 2020 Interim Analysis N ≥ 2.9 mg/kg* 25 (20 evaluable) 34 (33 evaluable) Median Age 61 (47–76) 61 (48–79) Median Prior Lines 5 (2–10) 5 (2–10) Improved Efficacy Out
Slide 17: Summary and Next Steps in Clinical Development
STRO 002 Summary and Next Steps in Clinical Development STRO-002 is clinically efficacious at multiple doses, starting at 2.9 mg/kg Dose reductions or delays were not associated with loss of anti-tumor activity Further dose optimization will be explored during dose expansion Anticipate RP2D will be
Slide 18: CD74-Targeting ADC STRO-001
CD74-Targeting ADC: Phase 1 Potential First and Best-in-Class ADC for B-Cell Malignancies STRO 001
Slide 19: STRO-001 Structure and Design
STRO-001Structure and Design First-in-class Molecule with Potential for Improved Patient Outcomes STRO 001 STRO-001 STRO-001 is a novel homogeneous antibody-drug conjugate using precisely positioned non-natural amino acids STRO-001 comprises two non-cleavable maytansinoid linker-warheads (DAR=2) tha
Slide 20: Patient Demographics
Patient Demographics First 25 Patients – ASH Abstract November 2019 Characteristics Cohort A (MM) N =14 Cohort B (NHL) N=11 Total N=25 Age, median (range), years 64.5 (42–80) 64 (21–82) 64 (21–82) Median time from diagnosis in years (range) Disease Subtype, N (%) Multiple myeloma 14 (100) N/A 14 (56
Slide 21: Generally Well Tolerated with Early Signs of Anti-Tumor Activity
Generally Well Tolerated with Early Signs of Anti-Tumor Activity Presented at EHA June 2019 and Updated in ASH Abstract November 2019 STRO 001 STRO-001 was generally well tolerated, most AEs were Grade 1 & 2 No ocular toxicity signals have been observed Preliminary anti-tumor activity: DLBCL: 1CR &
Slide 22: CC-99712 (BCMA-Targeting ADC) Phase 1B/2 Study
CC–99712 (BCMA-Targeting ADC) Phase 1B/2 Study Potential for Best-In-Class Ongoing Study of Dose Escalation (Q3W) N O OO NH OH OCH3 O N O O Cl H3CO O N O O OOOON N H O N N N Site-specific conjugation leads to Drug-antibody Ratio (DAR) = 4 CC-99712 Molecule DL3 N=1 N=1 N=4 N=3-6 0.6 mg/kg N = 2 2.0 m
Slide 23: M1231 (MUC1-EGFR Bispecific ADC) Potential for First-In-Class
M1231 (MUC1-EGFR Bispecific ADC) Potential for First-In-Class – 1Q21 First In Human Planned First bispecific ADC to go to clinic; M1231 targets MUC1 & EGFR Combines next generation technologies; stable site-specific XpressCF+™ conjugation, optimized positioning of a proprietary hemiasterlin payload
Slide 24: M1231 Strong Efficacy in Preclinical NSCLC & Esophageal Cancer PDX Models
A single M1231 application was associated with complete remission in a subset of preclinical NSCLS and sqCC esophageal PDX models Tumor response seems to be associated with target expression M1231 (MUC1-EGFR Bispecific ADC) Strong efficacy in preclinical NSCLC & esophageal cancer PDX models Source:
Slide 25: Sutro's Next Generation Tumor Targeting Immunostimulatory ADC
Sutro’s Next Generation Tumor Targeting Immunostimulatory ADC Off the shelf, systemically administered in situ immunization Breakthrough technology for dual conjugated immunostimulatory antibody drug conjugate Designed and enabled using Sutro’s XpressCF+TM platform Enables simultaneous and precise t
Slide 26: Immunostimulatory ADC Provides Enhanced Immune Cell Activation and Anti-Tumor Immunity
Immunostimulatory ADC Provides Enhanced Immune Cell Activation and Anti-Tumor Immunity Early activation of Dendritic Cells Spleen of treated mice Control iADC (Cytotoxin + TLR agonist) ADC (Cytotoxin alone) ISAC (TLR agonist alone) iADC single dose causes some complete responses MC38-hFolR mouse mod
Slide 27: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Chief Executive Officer and Member of the Board of Directors Trevor Hallam, PhD Chief Scientific Officer Arturo Molina, MD, MS, FACP Chief Medical Officer Ed Albini Chief Financial Officer Shabbir Anik, PhD Chief Technical Operations Officer Linda Fitzp
Slide 28: Company Overview 2020 Wells Fargo Virtual Healthcare Conference
Company Overview 2020 Wells Fargo Virtual Healthcare Conference NASDAQ: STRO Bill Newell, CEO
Sutro Biopharma — 2020 Wells Fargo Virtual Healthcare Conference on 6ix